As a type of chemotherapy medication, Stivarga® (regorafenib) is prescribed to treat colorectal cancer (cancer of the colon and rectum) that has spread to other areas of the body. It is approved for use in adults only, and is reserved for use when the cancer has progressed after treatment with other chemotherapy.
It comes as a tablet that is usually taken once daily in the morning. Stivarga should be taken with a low-fat breakfast that contains less than 30 percent fat.
If your healthcare provider recommends chemotherapy treatment with Stivarga, he or she will need information on your medical history and any other medications, vitamins, or supplements you are using. Side effects are common and may include diarrhea, fatigue, and mouth sores. You should also talk to your healthcare provider before starting Stivarga if you are pregnant or have any allergies.
(For more information on this chemotherapy drug, click Stivarga. This full-length article discusses how the medicine works, other important warnings and precautions, and more.)
Food and Drug Administration (FDA) news release. FDA approves new treatment for advanced colorectal cancer. September 27, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321271.htm. Accessed October 9, 2012.
Micromedex 2.0 Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare), Inc. Updated periodically. Accessed October 9, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click